$76.500
-0.069 (-0.09%)Zum Schluss
BBIO-News
BBIO-Events
BridgeBio Pharma Files $500M Mixed Securities Shelf
BridgeBio Pharma files $500M mixed securities shelf
BridgeBio Pharma Presents New Analyses of Attruby Study at ESC 2026
BridgeBio Pharma presented new analyses from the Phase 3 ATTRibute-CM study of Attruby in transthyretin amyloid cardiomyopathy, ATTR-CM, including the cardiac magnetic resonance imaging, CMR, substudy and the open-label extension, OLE, at the European Society of Cardiology, ESC, Congress 2026. Acoramidis is the only selective small molecule, orally administered, near-complete transthyretin, TTR, stabilizer. The study found: In a completer analysis, clinically meaningful improvement from baseline in left ventricular systolic function was observed in 54% of acoramidis-treated patients versus 20% of placebo-treated patients at Month 30, and in 53% of continuous-acoramidis patients at Month 42; For context, only 26% of completers in an independent natural history cohort demonstrated improved LV systolic function by Month 24 - approximately half the rate observed with acoramidis, suggesting that this magnitude of improvement falls outside the expected natural course of disease; In a conservative analysis, long-term acoramidis treatment was associated with clinically meaningful improvement from baseline in LV systolic function in approximately one-third of patients over 30-42 months. Improvement was observed in 34% of acoramidis-treated patients versus 9% of placebo-treated patients at Month 30 and in 30% of continuous-acoramidis patients at Month 42; In addition, 46% of patients receiving continuous acoramidis demonstrated improvement from baseline in LV mass index at Month 42, providing evidence of favorable structural remodeling; These results provided sufficient evidence for BridgeBio to recently dose its first participant in ASCEND-ATTR, a Phase 3b/4 study designed to determine if acoramidis is associated with sustained improvement in myocardial structural disease progression, function and amyloid burden
BridgeBio Pharma Doses First Participant in ASCEND-ATTR Study
BridgeBio Pharma announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study designed to further characterize the long-term effects of acoramidis on the improvement of cardiac structure, function, and amyloid burden in individuals with transthyretin amyloid cardiomyopathy.
BridgeBio Pharma Launches Secondary Offering of 5M Shares
BridgeBio Pharma announced the launch of a secondary public offering of 5M shares of its common stock by the selling stockholder KKR Genetic Disorder. The company is not selling any shares and will not receive any of the proceeds of the offering. William Blair, Goldman Sachs & Co. and KKR are acting as joint book-running managers for the proposed offering.
BridgeBio Reports Q2 Revenue of $243.68M, Beating Expectations
Reports Q2 revenue $243.68M, consensus $219.71M. "I'm excited by the growing body of evidence continuing to demonstrate Attruby is the drug of choice for all ATTR-CM patients, and particularly for those who are treatment-naive, including the first-ever demonstration of early, sustained kidney-protective effects in ATTR-CM alongside the cardiac benefit we've established. Furthermore, this was the quarter all three of our pipeline programs, BBP-418, encaleret, and infigratinib, moved from data into active regulatory review, with our first PDUFA date now set for November 27, 2026, which is a level of strategic execution and discipline I'm proud of. Finally, with the $1 billion preferred equity financing we completed, we have a balance sheet sized to run all three launches at full strength, without diverting resources from the development engine that produced them," said Neil Kumar, Co-Founder and CEO of BridgeBio.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.